04X Stock Chart & Stats
€5.50
-€0.41(-6.77%)
At close: 4:00 PM EST
€5.50
-€0.41(-6.77%)
Day’s Range― - ―
52-Week Range€3.66 - €14.34
Previous CloseN/A
Volume0.00
Average Volume (3M)185.00
Market Cap
€1.11B
Enterprise Value€469.27
Total Cash (Recent Filing)€233.22M
Total Debt (Recent Filing)€38.78M
Price to Earnings (P/E)―
Beta0.16
Next Earnings
Aug 11, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.02
Shares Outstanding106,750,880
10 Day Avg. Volume240
30 Day Avg. Volume185
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-8.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.68Price Target Upside148.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.9
Revenue Forecast (FY)€69.36M
Bulls Say, Bears Say
Bulls Say
Clinical Volume AccelerationSustained and rapid clinical test volume growth indicates strong commercial adoption and physician traction. Higher test volumes create scale benefits across lab fixed costs, strengthen payer and provider familiarity, and support transition to reimbursed, higher-ASP workflows as adoption matures.
Expanded Medicare CoverageNew Medicare coverage validates clinical utility and materially expands addressable market among insured patients. Durable reimbursement removes a key commercialization barrier, enabling higher realized ASPs, more predictable revenue per test, and stronger long-term margin recovery if adoption continues.
Definitive Tempus Acquisition AgreementA pending acquisition by Tempus is a structural change that can accelerate commercialization, provide broader data/AI integration, and offer scale and capital support. Integration into a larger precision‑oncology platform can speed market access and reduce standalone execution and funding risk.
Bears Say
Severe Gross Margin CompressionA collapse in gross margin undermines the core economics of the testing business: low margins limit ability to cover R&D and SG&A sustainably. Margin recovery depends on volume conversion to reimbursed tests and higher-mix biopharma revenue; failure to restore margins risks persistent losses.
High Cash Burn And Negative Free Cash FlowMaterial projected cash usage (~$100M) and recurring negative operating cash flow (-$79.5M TTM) create financing and execution risk if revenue or reimbursement timing slips. Ongoing burn forces either dilution, asset sales, or reliance on partners/acquirers to sustain growth investments.
Dependence On Payer/MolDX TimingThe company’s margin recovery and higher-ASP ramp are contingent on variable MolDX and payer decisions. These external review processes are unpredictable; delays would prolong unreimbursed testing, compress realized margins, and defer the expected pathway to sustained profitability.
Personalis News
04X FAQ
What was Personalis’s price range in the past 12 months?
Personalis lowest stock price was €3.66 and its highest was €14.34 in the past 12 months.
What is Personalis’s market cap?
Personalis’s market cap is €1.11B.
When is Personalis’s upcoming earnings report date?
Personalis’s upcoming earnings report date is Aug 11, 2026 which is in 11 days.
How were Personalis’s earnings last quarter?
Personalis released its earnings results on May 07, 2026. The company reported -€0.253 earnings per share for the quarter, missing the consensus estimate of -€0.237 by -€0.017.
Is Personalis overvalued?
According to Wall Street analysts Personalis’s price is currently Undervalued.
Does Personalis pay dividends?
Personalis does not currently pay dividends.
What is Personalis’s EPS estimate?
Personalis’s EPS estimate is -0.23.
How many shares outstanding does Personalis have?
Personalis has 106,750,880 shares outstanding.
What happened to Personalis’s price movement after its last earnings report?
Personalis reported an EPS of -€0.253 in its last earnings report, missing expectations of -€0.237. Following the earnings report the stock price went down -2.759%.
Which hedge fund is a major shareholder of Personalis?
Currently, no hedge funds are holding shares in DE:04X
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Personalis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€13.68 (148.73% Upside)
€13.68 (148.73% Upside)
Blogger Sentiment
Neutral
DE:04X Sentiment 50%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Positive
20 days / 200 days
Momentum
75.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
19.06%
Trailing 12-Months
Company Description
Personalis
Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.
04X Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced strong operational and clinical momentum (rapid test volume growth, compelling real-world and study data, growing MRD pipeline, reimbursement wins and a healthy cash balance) against material near-term financial headwinds (severe gross margin compression, higher operating expenses, widening net loss and elevated cash burn). Management frames the negative margin and revenue mix trends as intentional investments to capture MRD market share and expects margins and ASPs to improve as reimbursed volume scales, but the timing of reimbursement and conversion to higher-margin revenue remains a key risk.View all DE:04X earnings summaries04X Stock 12 Month Forecast
Average Price Target
€13.68
▲(148.73% Upside)
Technical Analysis
Standard BioTools
―
Myriad Genetics
―
CareDx
―
Fulgent Genetics
―
Castle Biosciences
―